FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News
FibroGen Inc. (FGEN) announced after the bell Monday that its Phase 2 study of pamrevlumab in patients with idiopathic pulmonary fibrosis met the primary efficacy endpoint.
from RTT - Hot Stocks http://ift.tt/2wqmrnv
via IFTTT
No comments:
Post a Comment